Cleaved-MMP12 (G106) Antibody

What is Cleaved-MMP12 (G106) Antibody and what specific epitope does it recognize?

Cleaved-MMP12 (G106) Antibody is a rabbit polyclonal antibody that specifically detects endogenous levels of the activated fragment of MMP-12 protein resulting from cleavage adjacent to glycine at position 106 (G106) . This antibody was generated using a synthesized peptide derived from the internal region of human MMP-12, specifically within amino acids 87-136 . Unlike antibodies that detect the full-length MMP-12, this antibody is designed to recognize only the activated form, making it valuable for studying MMP-12 activation in biological processes .

The specificity for the cleaved form is critical because MMP-12 exists in both latent (54 kDa) and active (45 kDa) forms, and the antibody's ability to distinguish between these forms enables researchers to specifically monitor MMP-12 activation events .

What experimental applications are validated for Cleaved-MMP12 (G106) Antibody?

Cleaved-MMP12 (G106) Antibody has been validated for the following applications:

Western Blot (WB): Recommended dilution range of 1:500-1:2000

• Successfully tested on various cell lines including VEC cells and A549 cells

• Can detect the specific 45 kDa cleaved form of MMP-12

Enzyme-Linked Immunosorbent Assay (ELISA): Recommended dilution of 1:20000

• Suitable for quantitative measurement of cleaved MMP-12 in complex samples

While these are the primary validated applications, some researchers have adapted this antibody for other techniques including immunohistochemistry, though additional validation may be required for such applications .

What is the optimal sample preparation protocol for detecting cleaved MMP-12?

For optimal detection of cleaved MMP-12 using this antibody, consider the following sample preparation guidelines:

For Western Blot analysis:

• Extract total protein from cells or tissues using a lysis buffer containing protease inhibitors to prevent further proteolytic processing

• Quantify protein concentration using Bradford or BCA assay

• Load 20-40 μg of total protein per lane

• Separate proteins using 10-12% SDS-PAGE

• Transfer to PVDF or nitrocellulose membrane

• Block with 5% non-fat milk or BSA in TBST

• Incubate with primary antibody (1:500-1:2000) overnight at 4°C

• Wash and incubate with appropriate HRP-conjugated secondary antibody

For ELISA applications:

• Sample dilution may be required (linearity has been tested at 1:1, 1:2, 1:4, and 1:8 dilutions)

• Use 50-100 μl sample volume per well

• Average recovery rates of 93% from serum and 97% from EDTA plasma have been reported

What are the storage and handling recommendations for maintaining antibody performance?

To maintain optimal antibody performance, follow these storage and handling recommendations:

Storage conditions:

• Store at -20°C for up to 1 year from date of receipt

• Some manufacturers recommend storage at -80°C as an alternative

• Avoid repeated freeze-thaw cycles to prevent loss of activity

Formulation:

• The antibody is supplied as a liquid in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

• This formulation helps maintain stability during storage

Working solution handling:

• When preparing working dilutions, use freshly prepared buffers

• Keep working solutions on ice when not in use

• Return stock antibody to -20°C promptly after use

What species reactivity has been confirmed for this antibody?

The Cleaved-MMP12 (G106) Antibody has confirmed reactivity with:

Primary reactivity: Human (Homo sapiens) samples

Additional reported reactivity: Some product specifications indicate cross-reactivity with rat and mouse samples , though the primary immunogen is derived from human MMP-12 sequence.

When using this antibody with non-human samples, preliminary validation is strongly recommended to confirm cross-reactivity in your specific experimental system .

How can Cleaved-MMP12 (G106) Antibody be utilized to study MMP-12 activation in inflammatory diseases?

MMP-12 plays a significant role in inflammatory diseases, particularly in airway inflammation and remodeling . To effectively study MMP-12 activation in these contexts:

Experimental approach:

• Cell-specific activation studies: Use laser capture microdissection (LCM) to isolate specific cell populations from inflammatory tissues (e.g., airway smooth muscle cells), followed by protein extraction and Western blot analysis with Cleaved-MMP12 (G106) Antibody .

• Induction and regulation studies:

  • Treat cells with inflammatory stimuli (e.g., cytokines, growth factors)

  • Collect samples at different time points

  • Analyze MMP-12 cleavage/activation using Western blot with this antibody

  • Quantify results using densitometry normalized to appropriate loading controls

• Intervention studies:

  • Pre-treat cells with potential therapeutic compounds

  • Stimulate with inflammatory agents

  • Assess changes in MMP-12 activation using this antibody

  • Compare treated vs. untreated conditions to evaluate compound efficacy

Data interpretation considerations:

• The 45 kDa band represents the active form of MMP-12

• Changes in band intensity reflect alterations in MMP-12 activation rather than total protein expression

• For comprehensive analysis, pair with antibodies detecting total MMP-12 to calculate activation ratio

What are the technical considerations and troubleshooting strategies for Western blot analysis with this antibody?

For optimal Western blot results with Cleaved-MMP12 (G106) Antibody, consider these technical aspects:

Protocol optimization:

Common issues and solutions:

• No signal:

  • Confirm protein transfer with reversible stain

  • Verify primary antibody reactivity with positive control sample (e.g., VEC or A549 cells)

  • Ensure secondary antibody is functioning properly

• High background:

  • Increase washing steps (5x 5 minutes with TBST)

  • Increase antibody dilution

  • Use fresh blocking buffer

  • Consider adding 0.05-0.1% Tween-20 to antibody diluent

• Multiple bands:

  • Include peptide competition assay using the immunizing peptide to identify specific bands

  • Optimize protein extraction to minimize degradation

  • Consider pre-clearing lysates with protein A/G beads

• Inconsistent results:

  • Standardize protein extraction and quantification methods

  • Prepare fresh working solutions for each experiment

  • Include internal loading controls in each experiment

What protocols enable accurate quantification of cleaved MMP-12 using ELISA methodology?

For accurate quantification of cleaved MMP-12 using ELISA methodology with this antibody:

Sandwich ELISA protocol:

• Plate preparation:

  • Coat 96-well plates with capture antibody (typically another MMP-12 antibody)

  • Incubate overnight at 4°C

  • Wash with PBS-T and block with 1-5% BSA

• Sample preparation:

  • Dilute samples to fall within the standard curve range (0.625-40 ng/mL)

  • Prepare standards using recombinant MMP-12

  • For serum/plasma samples, dilutions of 1:1 to 1:8 have shown good linearity

• Detection:

  • Add samples and standards to plate

  • Incubate with Cleaved-MMP12 (G106) Antibody (1:20000 dilution)

  • Add HRP-conjugated secondary antibody

  • Develop with TMB substrate and measure absorbance at 450 nm

Performance metrics to expect:

• Intra-assay precision (CV%): <8%

• Inter-assay precision (CV%): <10%

• Recovery from serum: 88-98%

• Recovery from EDTA plasma: 92-107%

• Detection range: 0.625-40 ng/mL

• Sensitivity: 0.156 ng/mL

Quality control measures:

• Include positive and negative controls in each assay

• Run all samples in duplicate or triplicate

• Verify results with alternative methods (e.g., Western blot) when possible

How can researchers validate the specificity of Cleaved-MMP12 (G106) Antibody in their experimental systems?

Validating antibody specificity is crucial for experimental rigor. For Cleaved-MMP12 (G106) Antibody, consider these validation approaches:

Positive controls:

• Use cell lines known to express MMP-12 after appropriate stimulation (e.g., VEC cells, A549 cells)

• Include recombinant MMP-12 protein (both pro-form and activated form)

• Use samples treated with agents known to induce MMP-12 activation (e.g., etoposide 25 μM)

Negative controls:

• Include MMP-12 knockout or knockdown samples when available

• Use cell lines that do not express MMP-12

• Pre-absorb antibody with immunizing peptide (peptide competition assay)

Cross-reactivity assessment:

• Test against recombinant proteins of related MMPs (e.g., MMP-1, MMP-3, MMP-9)

• Compare detection patterns with other validated MMP-12 antibodies

• Confirm protein identity by mass spectrometry following immunoprecipitation

Molecular validation:

• Size verification: Confirm that the detected band is the expected size for cleaved MMP-12 (approximately 45 kDa)

• Functional correlation: Correlate antibody signal with elastolytic activity assays to confirm functional relevance

What role does cleaved MMP-12 play in tissue remodeling and how can this antibody contribute to mechanistic studies?

MMP-12 is involved in tissue injury and remodeling with significant elastolytic activity . The Cleaved-MMP12 (G106) Antibody can be instrumental in elucidating these mechanisms:

Biological functions of MMP-12 in tissue remodeling:

• Degrades soluble and insoluble elastin

• May play a role in aneurysm formation

• Associated with lung function and chronic obstructive pulmonary disease (COPD)

• Involved in extracellular matrix breakdown during normal physiological processes and disease

Mechanistic study approaches using this antibody:

• Cellular localization studies:

  • Combine with cellular fractionation to determine localization of activated MMP-12

  • Correlate with extracellular matrix degradation patterns

• Activation kinetics:

  • Monitor time-dependent activation following various stimuli

  • Establish temporal relationship between MMP-12 activation and tissue remodeling events

• Substrate specificity analysis:

  • Correlate MMP-12 activation (detected by this antibody) with degradation of specific matrix components

  • MMP-12 has preference for:

    • Leucine at the P1' site

    • Aromatic or hydrophobic residues at the P1 site

    • Small hydrophobic residues (preferably alanine) at P3

• Signaling pathway integration:

  • Examine relationship between MMP-12 activation and transcription factor activity (e.g., AP-1 family)

  • Identify signaling pathways that regulate MMP-12 activation using specific inhibitors

• Tissue-specific remodeling:

  • Study MMP-12 activation in specific tissues (e.g., lung, vasculature)

  • Correlate with histological changes and functional outcomes

These approaches can help researchers better understand how MMP-12 activation contributes to both normal tissue homeostasis and pathological conditions involving tissue remodeling.

How do various experimental conditions affect the detection of cleaved MMP-12, and what controls should be included?

Experimental conditions can significantly influence cleaved MMP-12 detection. Researchers should consider:

Sample preparation factors:

Experimental controls:

• Activation controls:

  • Positive control: Samples treated with activators (e.g., aminophenylmercuric acetate, APMA)

  • Negative control: Samples treated with MMP inhibitors (e.g., GM6001)

• Technical controls:

  • Loading control: Total protein stain or housekeeping protein

  • Antibody specificity control: Peptide competition

  • Sample processing control: Same sample processed with and without protease inhibitors

• Biological controls:

  • Paired unstimulated controls for each experimental condition

  • Time course samples to demonstrate dynamic changes

  • Genetic controls (siRNA knockdown or CRISPR knockout of MMP-12)

Validation across multiple techniques:

• Confirm antibody detection results with functional activity assays

• Correlate protein detection with mRNA expression using RT-PCR

• Consider zymography as a complementary technique to assess enzymatic activity

What are the emerging applications of Cleaved-MMP12 (G106) Antibody in research on pathological conditions?

The specific detection of activated MMP-12 enables several emerging research applications:

Pulmonary disease research:

• Investigation of MMP-12 activation in COPD pathogenesis

• Analysis of airway smooth muscle cell involvement in asthma

• Study of MMP-12 role in pulmonary fibrosis and tissue remodeling

Cardiovascular research:

• Examination of MMP-12 activation in aneurysm formation and progression

• Investigation of vascular remodeling in atherosclerosis

• Analysis of MMP-12 contribution to plaque instability

Cancer research:

• Study of MMP-12 activation in tumor microenvironment remodeling

• Investigation of potential prognostic value in specific cancer types

• Analysis of MMP-12 role in tumor invasion and metastasis

Inflammatory disease research:

• Monitoring MMP-12 activation as a biomarker of macrophage activation

• Study of tissue damage mechanisms in chronic inflammatory conditions

• Investigation of MMP-12 as a therapeutic target

Translational applications:

• Development of MMP-12 activation-specific assays for diagnostic purposes

• Screening of compounds that inhibit MMP-12 activation

• Monitoring of therapeutic efficacy in conditions where MMP-12 plays a pathological role

Methodological innovations:

• Combination with single-cell analysis techniques to study cell-specific activation patterns

• Integration with advanced imaging methods to visualize MMP-12 activation in tissues

• Development of multiplexed assays to study MMP-12 activation alongside other proteases